News

Investors of BioAge Labs Encouraged to Explore Legal Options

Investors of BioAge Labs Encouraged to Explore Legal Options

Legal Action Consideration for BioAge Labs Investors

Investors in BioAge Labs, Inc. are currently facing significant stock price declines following highly concerning news about the company's clinical trials. This situation has led Glancy Prongay & Murray LLP, a prominent national shareholder rights law firm, to encourage those affected to inquire regarding potential participation in a securities fraud class action lawsuit.

Understanding the Background

In September 2024, BioAge Labs executed an initial public offering (IPO), releasing 12.65 million shares at an opening price of $18 each. Initial responses from the market were optimistic; however, the outlook rapidly changed following a critical announcement from the company on December 6, 2024.

The Announcement's Impact

The announcement revealed that BioAge would halt the STRIDES Phase 2 study of its investigational drug candidate azelaprag due to observed liver complications in some participants. This disclosure resulted in a catastrophic stock decline of $15.44 per share, amounting to a staggering 76.85% drop, with shares closing at just $4.65 by December 9, 2024.

Investor Losses**

As a result of these events, investors have sustained considerable financial losses. Since the IPO, BioAge's stock has plummeted more than 67%, currently trading at only $5.82. This downturn raises serious concerns regarding the information disclosed to potential investors during the IPO process.

The Class Action Lawsuit Explained

The class action lawsuit alleges that BioAge and its representatives made several materially false or misleading statements regarding the company’s business health and future prospects. These claims further highlight critical details that were allegedly not disclosed to investors, affecting their decision-making.

Key Allegations in the Lawsuit

Among the important points raised in the lawsuit are allegations that the company failed to inform investors about significant risks associated with liver transaminitis discovered in past clinical trials. Moreover, it is claimed that these undisclosed risks misled investors regarding the feasibility of completing the ongoing STRIDES trial and its promised results.

Consequences of Misleading Information

The plaintiffs in this class action argue that these misleading statements contributed directly to the enormous losses investors have experienced. By overstating the success of their clinical trials and the safety of their drug, the company left investors unprepared for the devastating news that led to financial ruin for many.

Acting on Your Rights

Those who purchased or acquired BioAge's securities around the time of the IPO have until March 10, 2025, to file a motion to be recognized as lead plaintiffs in the class action. It is crucial for impacted investors to understand their rights and options in this challenging situation.

How to Get Involved?

Investors wishing to discuss their circumstances or who have suffered losses due to BioAge's actions are encouraged to reach out for more information. Engaging with a legal professional can provide essential guidance on how to proceed in the case of securities fraud.

Contact Information for Further Inquiry

For additional details or to express your interest in participating in this lawsuit, please connect with Charles Linehan, Esq. from Glancy Prongay & Murray LLP. The law firm's contact information is structured as follows:

Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, California 90067
Email: contact
Phone: 310-201-9150,
Toll-Free: 888-773-9224
Visit their website for updates.

Frequently Asked Questions

What triggered the lawsuit against BioAge Labs?

The lawsuit was initiated due to significant stock declines experienced after unfavorable news about a halted clinical trial.

Who can participate in the class action?

Investors who acquired BioAge securities during the IPO period may join the class action.

What is the deadline for filing a motion?

Investors have until March 10, 2025, to file a motion to be lead plaintiffs in the lawsuit.

What are the key allegations in the lawsuit?

The lawsuit alleges misinformation regarding the safety of surgical trials and misleading statements about the company's future.

How can I get more information about the lawsuit?

Interested parties should contact Glancy Prongay & Murray LLP for more details regarding participation in the lawsuit.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 372

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 174

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 200

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 186

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 268

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 203

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 257

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 253

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 170

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading

Top 5 Most Recently Viewed Articles

Nevada King Gold Corp. Advances Phase 3 Drill Program

Updated Category News Views 64

Nevada King Gold Corp. Advances Phase 3 Drill Program Nevada King Gold Corp. (TSXV: NKG) (OTC: NKGFF), fondly referred to as Nevada King, is taking exciting steps forward as it embarks on its Phase III regional drill program. Recently, the company achieved a crucial milestone by receiving a Finding of No Significant Impact (FONSI) approval from the U.S. Bureau of Land...

Continue Reading
Understanding the Complexities of American Household Wealth Dynamics

Updated Category News Views 128

Reevaluating American Household Wealth A recent paper presented at the Mercatus Center sheds light on a critical topic: American household wealth might not be as substantial as it initially appears. The paper, titled “We Are Not as Wealthy as We Thought We Were,” articulates essential economic observations that may surprise many. The Illusion of Real Estate Wealth...

Continue Reading
Terran Orbital Corporation Investors May Have Class Action Rights

Updated Category News Views 94

Overview of the Allegations Against Terran Orbital Corporation Investors in Terran Orbital Corporation (NYSE: LLAP) may find themselves in a position to lead a class action lawsuit against the company. The firm of Rosen Law has announced the initiation of such a lawsuit for those who purchased shares between certain timestamps. The legal actions arise from claims of...

Continue Reading
Expanding Horizons: Town Square Dermatology's New Chapter

Updated Category News Views 135

Transformative Partnership in Dermatologic Care Epiphany Dermatology, renowned for its commitment to exceptional dermatologic services, has made significant strides by partnering with Town Square Dermatology. This collaboration enables Epiphany to enhance its reach in Iowa, affirming its mission of improving access to quality skin care. Celebrating the Legacy of Town...

Continue Reading
Hertz's Initiative to Encourage Voting with Free Day Rental

Updated Category News Views 71

Hertz Encourages Voter Participation with Free Rental Day As election day approaches, Hertz is stepping up to help citizens across the nation get to the polls with their exciting promotion called the Free Day on Election Day. This generous initiative offers customers one day free when reserving a rental car for at least two days, providing a crucial service during an...

Continue Reading